MJMD: Savage, it looks more interesting now than when I took a gander a while ago. Audited fins; OTCQB tier. Likelihood of suspension appears very low from what I can see.
You're right about MJMD having characteristics of both BBio and PJ. It seems the lenders, by agreeing to settle some debt, are trying to help this get a decent start. CEO canceled 5mil of his shares, too. Co. sold 325,000 restricted to obtain $300,600 in working capital.
General and administrative expenses were unusually high at $583,898, but that included $551,000 of non-cash expenses (stock options) this time.
The stock chart shows PPS now trading at a triple bottom (three months). As of 06/13/2014, O/S 89,525,000. PPS at 0.66. Market Cap = $59mil.
There just getting started in the MMJ arena, having converted over from an Oil & Gas outfit.
All in all, it looks promising as they begin. Going forward, it depends, of course, on how their licensed products (delivery methods for cannabis doses) are received and whether they can make hay with online ordering in CA; no mention of payment method(s).
PJ style: "On May 13, 2014, the Company entered into a distribution agreement with GoKush.com (www.gokush.com) that is part of a not-for-profit California Cooperative Corporation that is dedicated to providing safe and legal access to medical marijuana for patients throughout California. Pursuant to the Agreement, amongst other things, the Company has agreed to issue GoKush 200,000 shares of the Company’s restricted common stock and GoKush agreed to become the online ordering platform for the ordering and re-stock of the Company’s products in California."
BBio style:
1. MediJane Transdermal Patches. Developed out of the commitment for accurate dosing and the application of pharmaceutical grade delivery methods within the cannabis industry. The registrant licensed a safe effective way to consume cannabis – transdermally. Six (6) formulations of patches are in development with ongoing research for many more to come. The patches shall retail for approximately $8-$12.50 per patch.
2. MediJane Capsules. Activated cannabinoid capsules that contain specific non-psychoactive and psychoactive ratios utilizing natural uptake agents for low dose flexibility for controlling inflammation, muscle spasms, neuropathic pain and many other ailments. Our advanced formulation techniques have allowed us to create standards of cannabinoid profiles for specific medical conditions with enhanced nutritional additives, allowing the body to provide sustainable health. The capsules shall retail at $50-$75 per package.
3. Vaporizing Pharmaceutical Grade Cannabis. Vaporizing is a common technique for consuming marijuana, while, at the same time, negating many irritating respiratory toxins that exits within the grown marijuana flower and are released when smoked. Conversely, vaporizing allows one to get at all of the psychoactive, pain management and anti-inflammatory ingredients available within that specific strain of cannabis, minus the combustion that ordinarily takes place during consumption. Each product package shall retail at $50-$75 per package.
4. Canna-Mist Oral Spray. Sublingual sprays provide effective, fact acting cannabinoid delivery because they allow direct access to the blood stream. Each spray of MediJane Canna-mist delivers 2.5 mg of cannabinoids. Every patient’s metabolism is different and dosage needs vary. The recommended dosage commences with one or two sprays and build up from there based on need. Each bottle shall retail for $45-$60 per bottle.
###
License Agreement. On March 14, 2014, the registrant entered into a license agreement with Phoenix Bio Pharmaceuticals Corporation (“Phoenix Bio Pharm”). Pursuant to the license agreement, Phoenix Bio Pharm has granted to the registrant an exclusive license for the territory of North America to exploit all presently owned and after-acquired intellectual property rights and know-how of Phoenix Bio Pharm related to certain medical cannabinoid products and delivery systems for the treatment and management of illnesses. Products falling under the license will include the following medicinal cannabis products: transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and extraction technology, suppository delivery systems, salves, creams, gels, lotions, and liquid extracts, and any products or active ingredients sourced through Phoenix Bio Pharm affiliates or third party suppliers or licensors.
The registrant will also have the right to sublicense the rights acquired pursuant to the license agreement and to use and develop copyrighted materials of Phoenix Bio Pharm for marketing and distribution purposes. In consideration of the acquired license, the registrant issued 26,000,000 common shares to Phoenix Bio Pharm.
###
Debt reduction:
At February 28, 2014, the registrant had total liabilities of $10,436 compared with $543,266 at February 28, 2013. The decrease in total liabilities was attributed to decreased amounts due to related parties of $58,150, convertible debentures of $215,000 and derivative liability of $227,507, and decreased accounts payable of $32,648. The decreased notes payable, convertible debentures and derivative liabilities is due to reductions in liability from the waivers received from each of the parties under these instruments. The registrant has recorded a gain of $384,013 and $227,507, on the settlement of debt and derivative liabilities, respectively.
You're right about MJMD having characteristics of both BBio and PJ. It seems the lenders, by agreeing to settle some debt, are trying to help this get a decent start. CEO canceled 5mil of his shares, too. Co. sold 325,000 restricted to obtain $300,600 in working capital.
General and administrative expenses were unusually high at $583,898, but that included $551,000 of non-cash expenses (stock options) this time.
The stock chart shows PPS now trading at a triple bottom (three months). As of 06/13/2014, O/S 89,525,000. PPS at 0.66. Market Cap = $59mil.
There just getting started in the MMJ arena, having converted over from an Oil & Gas outfit.
All in all, it looks promising as they begin. Going forward, it depends, of course, on how their licensed products (delivery methods for cannabis doses) are received and whether they can make hay with online ordering in CA; no mention of payment method(s).
PJ style: "On May 13, 2014, the Company entered into a distribution agreement with GoKush.com (www.gokush.com) that is part of a not-for-profit California Cooperative Corporation that is dedicated to providing safe and legal access to medical marijuana for patients throughout California. Pursuant to the Agreement, amongst other things, the Company has agreed to issue GoKush 200,000 shares of the Company’s restricted common stock and GoKush agreed to become the online ordering platform for the ordering and re-stock of the Company’s products in California."
BBio style:
1. MediJane Transdermal Patches. Developed out of the commitment for accurate dosing and the application of pharmaceutical grade delivery methods within the cannabis industry. The registrant licensed a safe effective way to consume cannabis – transdermally. Six (6) formulations of patches are in development with ongoing research for many more to come. The patches shall retail for approximately $8-$12.50 per patch.
2. MediJane Capsules. Activated cannabinoid capsules that contain specific non-psychoactive and psychoactive ratios utilizing natural uptake agents for low dose flexibility for controlling inflammation, muscle spasms, neuropathic pain and many other ailments. Our advanced formulation techniques have allowed us to create standards of cannabinoid profiles for specific medical conditions with enhanced nutritional additives, allowing the body to provide sustainable health. The capsules shall retail at $50-$75 per package.
3. Vaporizing Pharmaceutical Grade Cannabis. Vaporizing is a common technique for consuming marijuana, while, at the same time, negating many irritating respiratory toxins that exits within the grown marijuana flower and are released when smoked. Conversely, vaporizing allows one to get at all of the psychoactive, pain management and anti-inflammatory ingredients available within that specific strain of cannabis, minus the combustion that ordinarily takes place during consumption. Each product package shall retail at $50-$75 per package.
4. Canna-Mist Oral Spray. Sublingual sprays provide effective, fact acting cannabinoid delivery because they allow direct access to the blood stream. Each spray of MediJane Canna-mist delivers 2.5 mg of cannabinoids. Every patient’s metabolism is different and dosage needs vary. The recommended dosage commences with one or two sprays and build up from there based on need. Each bottle shall retail for $45-$60 per bottle.
###
License Agreement. On March 14, 2014, the registrant entered into a license agreement with Phoenix Bio Pharmaceuticals Corporation (“Phoenix Bio Pharm”). Pursuant to the license agreement, Phoenix Bio Pharm has granted to the registrant an exclusive license for the territory of North America to exploit all presently owned and after-acquired intellectual property rights and know-how of Phoenix Bio Pharm related to certain medical cannabinoid products and delivery systems for the treatment and management of illnesses. Products falling under the license will include the following medicinal cannabis products: transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and extraction technology, suppository delivery systems, salves, creams, gels, lotions, and liquid extracts, and any products or active ingredients sourced through Phoenix Bio Pharm affiliates or third party suppliers or licensors.
The registrant will also have the right to sublicense the rights acquired pursuant to the license agreement and to use and develop copyrighted materials of Phoenix Bio Pharm for marketing and distribution purposes. In consideration of the acquired license, the registrant issued 26,000,000 common shares to Phoenix Bio Pharm.
###
Debt reduction:
At February 28, 2014, the registrant had total liabilities of $10,436 compared with $543,266 at February 28, 2013. The decrease in total liabilities was attributed to decreased amounts due to related parties of $58,150, convertible debentures of $215,000 and derivative liability of $227,507, and decreased accounts payable of $32,648. The decreased notes payable, convertible debentures and derivative liabilities is due to reductions in liability from the waivers received from each of the parties under these instruments. The registrant has recorded a gain of $384,013 and $227,507, on the settlement of debt and derivative liabilities, respectively.
